Gene-Specific Demethylation as Targeted Therapy in MDS
Abstract
Myelodysplastic Syndromes (MDS) are a group of clonal hematopoietic disorders characterized by bone marrow failure and risk of progression to Acute Myeloid Leukemia (AML) in approximately 30 percent of the cases. Aberrant DNA methylation is considered a dominant mechanism for Tumor Suppressor Genes silencing during MDS evolution to AML, but the causes leading to aberrant DNA methylation remain elusive. This proposal builds on our recent discovery of a novel class of RNAs, the DiRs or DNMT1-interacting RNAs, involved in cell type-specific DNA methylation patterns. Based on these findings, we hypothesize that DNA methylation changes can be corrected by RNAs.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jul 01, 2017
- Accession Number
- AD1044910
Entities
People
- Daniel G Tenen
Organizations
- Beth Israel Deaconess Medical Center